Arcellx Announces Clinical Hold For Its iMMagine-1 Phase 2 Clinical Program; FDA Has Provided Clearance To The Co To Continue Dosing Patients Who Have Already Undergone Lymphodepletion
Portfolio Pulse from Happy Mohamed
Arcellx has announced a clinical hold on its CART-ddBCMA investigational new drug for the treatment of relapsed or refractory multiple myeloma (rrMM) following a recent patient death. The FDA has allowed the company to continue dosing patients who have undergone lymphodepletion.
June 19, 2023 | 11:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arcellx's clinical hold on its CART-ddBCMA program may negatively impact investor sentiment and the company's stock price.
The clinical hold on Arcellx's CART-ddBCMA program comes after a recent patient death, which may raise concerns among investors about the safety and future prospects of the drug. This could lead to a negative impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100